drug_type
RELEVANT_DRUG
intervention_type
Gene-modified cellular immunotherapy (CAR-T)
drug_description
Patient-derived T cells engineered to express a chimeric antigen receptor targeting CD7; CAR engagement activates T-cell effector functions (TCR-like signaling, perforin/granzyme release, cytokine secretion) to kill CD7+ malignant T cells. Expected on-target effects include depletion of normal CD7+ T cells and some NK cells, leading to T-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD7. CAR engagement triggers TCR-like signaling and costimulation, inducing cytotoxicity (perforin/granzyme) and cytokine release to eliminate CD7+ malignant T cells; expected on‑target effects include depletion of normal CD7+ T cells and some NK cells (T‑cell aplasia).
drug_name
Autologous CD7 CAR T-cell
nct_id_drug_ref
NCT06316427